Sacubitril valsartan
Indication
Treating symptomatic chronic heart failure with reduced ejection fraction (NICE TA388)
NICE TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Amber level 0
Brand:
Entresto®
Nice TA:
388
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
Sacubitril/valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:
• with New York Heart Association (NYHA) class II to IV symptoms and
• with a left ventricular ejection fraction of 35% or less and
• who are already taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).
Supporting information:
- Initiation should be by the specialist team.
- Specialist team to prescribe and monitor until patient is stabilised on optimised dose (2-3 weeks on optimised dose).
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: